Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,023 across all filing types
Latest filing 2025-07-30 Earnings Release
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
2nd Quarter Results
Earnings Release Classification · 100% confidence The document is a formal 'Results Announcement' from GSK PLC for the second quarter of 2025. It contains detailed financial performance metrics, including turnover, operating profit, EPS, and segment-specific sales data (HIV, Vaccines, Oncology, etc.). It also provides updated 2025 financial guidance, dividend declarations, and R&D pipeline updates. As this is the primary release of quarterly financial results, it is classified as an Earnings Release (ER). Q2 2025
2025-07-30 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2025-07-29 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is a regulatory announcement from GSK plc regarding the purchase of its own shares (share buyback). It includes specific details such as the number of shares purchased, price paid, and a detailed schedule of individual transactions on the London Stock Exchange. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-07-29 English
GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS
Regulatory Filings
2025-07-28 English
PRIMARY DOCUMENT
Regulatory Filings
2025-07-28 English
GSK enters Hengrui Pharma collaboration agreements
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) regarding a strategic partnership and licensing agreement between GSK and Hengrui Pharma for the development of innovative medicines. This type of corporate announcement regarding M&A or strategic business collaborations falls under the category of M&A Activity (TAR) as it involves a significant business development deal, licensing, and future milestone payments.
2025-07-28 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.